Pfiz­er fronts $250M to nab an­ti­sense drug from Akcea/Io­n­is in up to $1.5B deal

Ear­li­er this year, Pfiz­er se­cured ear­ly ap­proval of its tout­ed block­buster — tafamidis — for transthyretin-me­di­at­ed amy­loi­do­sis, a field ini­tial­ly di­vid­ed be­tween Al­ny­lam and Akcea/Io­n­is. Now the big drug­mak­er is li­cens­ing an an­ti­sense ther­a­py for cer­tain car­dio­vas­cu­lar and meta­bol­ic dis­eases from its small­er ri­val.

Un­der the agree­ment, Akcea $AK­CA and its sis­ter com­pa­ny Io­n­is $IONS — which owns a con­trol­ling in­ter­est in its stock — will re­ceive $250 mil­lion up­front, and up to $1.3 bil­lion in mile­stone pay­ments, in ad­di­tion to dou­ble-dig­it roy­al­ties.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.